Skip to content

Drug interactions

Ticlopidine + Tucatinib

Severity: Moderate

Ticlopidine and Tucatinib: moderate interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Tucatinib is a strong CYP3A inhibitor and can raise exposure of CYP3A substrates. Ticlopidine is partly metabolized by CYP3A4, so its levels and activation may be altered. Ticlopidine's hematologic toxicity makes unpredictable exposure undesirable.

What this interaction means in plain words

Ticlopidine and Tucatinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.

Ticlopidine belongs to Cardiovascular; Tucatinib belongs to Oncology.

Evidence level: Low

Why it happens

Tucatinib inhibits CYP3A4, which may alter the metabolism of ticlopidine.

What to do

Prefer an alternative antiplatelet agent. If coadministered, monitor blood counts and clinical response.

What to ask your pharmacist

  • Should I take them at different times of day?
  • Does the dose of either medicine need to change?
  • Is there anything I should avoid, such as alcohol or certain foods, while on both?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Ticlopidine and Tucatinib, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 14 days on the web. No card needed.

Frequently asked questions

Can I take Ticlopidine with Tucatinib?

MediHelp rates the interaction as moderate. Ticlopidine and Tucatinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Tucatinib is a strong CYP3A inhibitor and can raise exposure of CYP3A substrates. Ticlopidine is partly metabolized by CYP3A4, so its levels and activation may be altered. Ticlopidine's hematologic toxicity makes unpredictable exposure undesirable.

How serious is the interaction between Ticlopidine and Tucatinib?

MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Prefer an alternative antiplatelet agent. If coadministered, monitor blood counts and clinical response.

What other medicines interact with Ticlopidine?

MediHelp also lists interactions of Ticlopidine with, for example, Mavacamten, Abrocitinib, Acetylsalicylic acid. The full list is on the Ticlopidine page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in